GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

HPGC Renmintongtai Pharmaceutical 600829.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

8.88

+2.54%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in CNY, from our data supplier.

FY2025

Revenue

CN¥10.38bn

FY2016FY2025

Net income

CN¥133.8m

FY2016FY2025

Free cash flow

CN¥282.8m

FY2016FY2025

Shareholders' equity

CN¥3.02bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueCN¥10.38bnCN¥10.05bnCN¥10.39bnCN¥9.64bnCN¥9.32bnCN¥8.01bnCN¥8.35bnCN¥7.06bnCN¥8.01bnCN¥9.01bn
Gross profitCN¥854.1mCN¥858.5mCN¥986.1mCN¥907.1mCN¥984.5mCN¥903.5mCN¥1.00bnCN¥890.4mCN¥915.0mCN¥887.4m
Research and development—————————CN¥374,020
Operating incomeCN¥290.5mCN¥288.9mCN¥399.4mCN¥347.4mCN¥360.6mCN¥220.1mCN¥363.7mCN¥349.9mCN¥338.8mCN¥322.9m
Net incomeCN¥133.8mCN¥213.3mCN¥292.2mCN¥264.5mCN¥277.3mCN¥145.3mCN¥267.3mCN¥257.9mCN¥254.2mCN¥224.5m
Diluted earnings per share0.230.370.500.460.480.250.460.430.440.39

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsCN¥7.17bnCN¥7.17bnCN¥7.43bnCN¥7.06bnCN¥6.75bnCN¥6.00bnCN¥5.55bnCN¥4.41bnCN¥4.84bnCN¥4.81bn
Cash and short-term investments—CN¥1.10bnCN¥1.31bnCN¥1.18bnCN¥800.5mCN¥416.8mCN¥367.2mCN¥505.7mCN¥443.3mCN¥494.3m
Total liabilitiesCN¥4.16bnCN¥4.29bnCN¥4.68bnCN¥4.60bnCN¥4.55bnCN¥4.00bnCN¥3.70bnCN¥2.83bnCN¥3.23bnCN¥3.16bn
Debt—CN¥869.6mCN¥991.5mCN¥1.27bnCN¥1.33bnCN¥610.7mCN¥524.0mCN¥224.0mCN¥224.0mCN¥110.0m
Shareholders' equityCN¥3.02bnCN¥2.88bnCN¥2.75bnCN¥2.46bnCN¥2.20bnCN¥1.99bnCN¥1.85bnCN¥1.58bnCN¥1.61bnCN¥1.65bn
Shares outstanding581m580m580m580m580m585m580m604m580m580m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsCN¥300.0mCN¥115.4mCN¥333.0mCN¥307.3m−CN¥233.0m−CN¥9.2m−CN¥411.6mCN¥366.5mCN¥139.1mCN¥46.0m
Capital spending−CN¥17.2m−CN¥8.0m−CN¥23.5m−CN¥6.4m−CN¥12.2m−CN¥14.0m−CN¥8.3m−CN¥5.7m−CN¥7.1m−CN¥22.8m
Free cash flowCN¥282.8mCN¥107.4mCN¥309.5mCN¥300.9m−CN¥245.2m−CN¥23.2m−CN¥419.9mCN¥360.7mCN¥132.0mCN¥23.2m
Dividends paid−CN¥20.1m−CN¥160.4m−CN¥24.6m−CN¥30.5m−CN¥69.6m−CN¥4.3m−CN¥14.2m−CN¥299.0m−CN¥297.1m−CN¥5.2m

Latest quarters

By quarter end

Jun 2026Mar 2026Dec 2025Sept 2025Jun 2025Mar 2025Dec 2024Sept 2024
RevenueCN¥2.58bnCN¥2.82bnCN¥2.53bnCN¥2.70bnCN¥2.48bnCN¥2.67bnCN¥2.37bnCN¥2.69bn
Gross profitCN¥210.0mCN¥228.8mCN¥224.9mCN¥218.7mCN¥201.8mCN¥208.7mCN¥177.4mCN¥232.2m
Operating incomeCN¥62.9mCN¥89.8mCN¥60.2mCN¥52.8mCN¥39.1mCN¥60.7mCN¥18.9mCN¥93.7m
Net incomeCN¥32.5mCN¥48.5mCN¥22.0mCN¥39.3mCN¥26.7mCN¥45.8mCN¥7.3mCN¥70.8m
Diluted earnings per share0.060.080.040.070.050.080.010.12
Cash from operations———−CN¥187.0mCN¥176.0m−CN¥302.0mCN¥358.0m−CN¥38.0m
Capital spending−CN¥11.0m−CN¥1.0m−CN¥8.0m−CN¥6.0m−CN¥1.0m—−CN¥3.0m−CN¥1.0m
Free cash flow———−CN¥193.0mCN¥175.0m—CN¥355.0m−CN¥39.0m
Total assetsCN¥7.13bnCN¥7.35bnCN¥7.17bnCN¥7.02bnCN¥7.01bnCN¥7.20bnCN¥7.17bnCN¥7.03bn
Cash and short-term investments———CN¥620.3mCN¥876.3mCN¥745.7mCN¥1.10bnCN¥795.9m
Debt———CN¥1.93bnCN¥750.0mCN¥780.0mCN¥839.2mCN¥925.1m
Shareholders' equityCN¥3.10bnCN¥3.06bnCN¥3.02bnCN¥2.99bnCN¥2.95bnCN¥2.93bnCN¥2.88bnCN¥2.87bn

Financial ratios

Data as of 12 Oct 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2016FY2015FY2014FY2013FY2012FY2011
Gross margin8.2%8.5%9.5%9.4%10.6%11.3%———————
Operating margin2.1%3.2%4.1%4.1%4.5%3.2%———————
Net margin1.3%2.1%2.8%2.7%3.0%1.8%———————
Return on equity4.4%7.4%10.6%10.7%12.6%7.3%———————
Return on assets1.9%3.0%3.9%3.7%4.1%2.4%———————
Free cash flow yield5.9%2.3%6.6%5.8%-4.1%0.1%———————
Revenue growth3.3%-3.3%7.8%3.5%16.4%-4.2%———————
Earnings growth-37.2%-27.0%10.5%-4.6%90.9%-45.7%———————
Current ratio1.67x1.62x1.53x1.48x1.42x1.43x———————
Debt to equity—0.29x0.35x0.49x0.59x0.04x0.28x——————
Equity ratio42.0%40.2%37.0%34.9%32.6%33.2%———————
Interest coverage8.74x9.08x11.83x7.39x7.40x7.13x———————
R&D as a share of sales———————0.0%0.2%0.3%0.9%0.7%0.8%
Buybacks as a share of market value-0.2%0.1%-0.0%-0.0%0.8%-0.8%———————

Growth per year

Compound annual rate

3 years5 years10 years
Revenue2.5%5.3%1.5%
Operating income-5.8%5.7%2.8%
Net income-20.3%-1.6%-0.4%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin8.4%8.9%9.5%10.3%
Operating margin2.8%3.3%3.3%3.5%
Net margin1.7%2.2%2.3%2.5%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings46.920.415.514.014.129.914.813.727.939.5
Price to sales0.60.40.40.40.40.50.50.50.91.0

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 25 Jul 2024.

FY2024FY2021FY2018FY2017FY2014FY2011FY2010FY2009
Paid in the year0.1440.120.500.500.1330.3270.4530.493
  • 3-for-2 split · 14 Jun 2011
  • 3-for-2 split · 25 Aug 2004
  • 3-for-2 split · 23 Oct 2002
  • 13-for-10 split · 2 Jul 2002
  • 11-for-10 split · 7 Jul 1997
  • 11-for-10 split · 17 Jun 1996

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.